Use of tirzepatide (Mounjaro) in type 2 diabetes management: an overview.

Claire Davies

Journal: Nursing standard (Royal College of Nursing (Great Britain) : 1987) 2025;40(7):47-53

PMID: 40383978

Abstract

Diabetes mellitus is an increasingly common long-term metabolic disease. There are many treatment options available to manage type 2 diabetes and reduce the risk of associated long-term microvascular and macrovascular complications. The management of type 2 diabetes initially focuses on lifestyle changes, such as a healthy diet and increased physical activity levels, with pharmacological intervention used as an adjunct where necessary. Tirzepatide, sold under the brand name Mounjaro, is the latest pharmacological therapy to be developed for this condition. This article discusses the place of tirzepatide therapy as part of the management of type 2 diabetes. It explains the mechanism of action of this medicine, its administration and dosing, the potential side effects, and its cautions and contraindications.

© 2025 RCN Publishing Company Ltd. All rights reserved. Not to be copied, transmitted or recorded in any way, in whole or part, without prior permission of the publishers.

Address: Queen Elizabeth Hospital, Gateshead Health NHS Foundation Trust, Gateshead, England.

Link outs

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.